A Study of APG-3288 in Relapsed/Refractory Blood Cancers

This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.

Trial Details

NCT ID
NCT07424833
Phase
PHASE1
Sponsor
Ascentage Pharma Group Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • APG-3288
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • East Brunswick, New Jersey, United States|40.42788,-74.41598
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) status ≤ 1 in Part 1 (dose escalation), and ≤ 2 in Part 2 (dose expansion).
  • Part 1 (Dose Escalation): histologically or cytologically confirmed diagnosis of R/R CLL/SLL, DLBCL (including Richter Transformation), MCL, WM, MZ…
  • Prior systemic therapy: at least 2 prior lines of systemic therapy (including BTK inhibitor for approved indications) and who have failed or are no…
  • Measurable disease per response criteria specific to the malignant condition.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →